Islamabad: The Drug Regulatory Authority of Pakistan (DRAP) has achieved a significant milestone by being designated as an Observer at the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), as announced during the ICH Assembly in Rio de Janeiro, Brazil. This development marks a step forward in Pakistan’s efforts to establish a modern and globally integrated regulatory system, according to the Federal Minister for National Health Services, Regulations and Coordination.

According to the Press Information Department, the ICH is a platform that unites leading regulatory authorities and the pharmaceutical industry to develop harmonized technical guidelines. These guidelines ensure the quality, safety, and efficacy of medicines. By becoming an Observer, Pakistan aims to benefit from global best practices and contribute to the international regulatory dialogue. This engagement is anticipated to enhance regulatory capacity, improve transparency and efficiency, and boost confidence in Pakistan’s pharmaceutical system.

This observer status is expected to open new opportunities for Pakistan’s domestic industry to align with international standards and expand its global presence. It reflects the government’s commitment to modernizing public institutions and aligning with international regulatory practices. Syed Mustafa Kamal, the Federal Minister, highlighted the importance of this achievement in advancing towards internationally harmonized standards and ensuring high-quality medicines in Pakistan. The government also remains committed to supporting DRAP in achieving WHO Global Benchmarking Tool Maturity Level 3, an indicator of a stable regulatory system.

Looking forward, the Minister expressed optimism about DRAP’s continued progress toward full ICH membership and enhanced engagement with other international regulatory platforms, including the Pharmaceutical Inspection Co-operation Scheme. The Ministry reaffirmed its support for advancing regulatory excellence and ensuring improved access to safe and effective medicines.